文献速递药物相互作用

药物相互作用研究中代谢物药代动力学的采集:工业实践与数据利用综述

Collecting Metabolite Pharmacokinetics in Drug-Drug Interaction Studies: A Review of Industry Practices and Data Utilization.
PubMed 文献 · Clin Pharmacokinet · 2026-06-03

本综述检索了2014年9月至2024年9月期间常用CYP探针(咪达唑仑、氟比洛芬、奥美拉唑、安非他酮、瑞格列奈、右美沙芬)的临床DDI研究记录,分析代谢物终点的报告、母药与代谢物结果的一致性及代谢物数据在说明书推荐中的利用。结果显示,单通路代谢探针的代谢物数据未增加DDI检测敏感性且常不用于标签推荐,而多通路代谢探针的代谢物/母药比值比母药AUC更敏感;尿表型指数很少收集。作者据此提出了判断代谢物终点相关性的标准。

要点

  • 单通路代谢探针(咪达唑仑、氟比洛芬、奥美拉唑)的代谢物终点未增加DDI检测敏感性。
  • 多通路代谢探针(安非他酮、瑞格列奈)的代谢物/母药比值比母药AUC更敏感。
  • 尿表型指数(如右美沙芬)在DDI研究中很少收集。

核心结论

  • 基于常用CYP探针的DDI研究证据,作者提出了判断代谢物终点在临床DDI研究中相关性的标准。

研究设计与样本

  • 本综述检索了2014年9月至2024年9月期间常用CYP探针(咪达唑仑、氟比洛芬、奥美拉唑、安非他酮、瑞格列奈、右美沙芬)的临床DDI研究记录。

主要发现

  • 单通路代谢探针(咪达唑仑、氟比洛芬、奥美拉唑)的DDI研究常包括代谢物终点,但代谢物数据未增加DDI检测的额外敏感性,且常未用于标签推荐。
  • 多通路代谢探针(安非他酮、瑞格列奈)的DDI研究显示,代谢物/母药比值检测DDI的敏感性高于单用母药AUC。
  • 尿表型指数(如右美沙芬)在DDI研究中很少收集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Systemic exposure of a sensitive probe is considered a 'gold standard' for assessment of clinical relevance of a potential cytochrome P450 (CYP)-driven drug-drug interaction (DDI). Typically, the change in systemic exposure is judged by the area under the concentration-time curve [AUC]) of the parent, but sometimes metabolite exposure is used to further elucidate the mechanism of the DDI. METHODS: For this review, we retrieved records of clinical DDI studies conducted between September 2014 and September 2024 for commonly used CYP probes (midazolam [CYP3A4], flurbiprofen [CYP2C9], omeprazole [CYP2C19], bupropion [CYP2B6], repaglinide [CYP2C8], and dextromethorphan [CYP2D6]). We reviewed these records for reported systemic or urinary metabolite endpoints, concordance of parent and metabolite results, and utilization of metabolite data in clinical recommendations reflected in the label of the investigational medicinal product (IMP). RESULTS: Although DDI studies with probes primarily metabolized by a single pathway (i.e. midazolam, flurbiprofen, omeprazole) often included metabolite endpoints, metabolite data did not add additional sensitivity in detecting the DDI and often were not used in the label recommendations. In contrast, DDI studies with probes that are metabolized by several pathways (i.e. bupropion, repaglinide) demonstrated a higher sensitivity of metabolite-to-parent ratio to detect a DDI compared with use of the parent AUC alone. Urinary phenotyping indexes (as exemplified by dextromethorphan) are rarely collected. CONCLUSIONS: Based on these findings, we formulated criteria for deciding on the relevance of metabolite endpoints in clinical DDI studies.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Dubich T, van Iersel T, Mirdamadi K, et al. Collecting Metabolite Pharmacokinetics in Drug-Drug Interaction Studies: A Review of Industry Practices and Data Utilization. Clin Pharmacokinet. 2026. PMID: 42234077. doi:10.1007/s40262-026-01657-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。